AU StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

Industrial Minerals Ltd

0.115

0.000

Volume:- -

Turnover:3.16K

Market Cap:11.54M

PE:-12.58

High:0.115

Open:0.115

Low:0.115

Close:0.115

52wk High:0.200

52wk Low:0.092

Shares:100.32M

Float Shares:42.54M

Volume Ratio:- -

T/O Rate:- -

Dividend:- -

Dividend Rate:- -

EPS(TTM):-0.009

EPS(LYR):-0.030

ROE:-24.45%

ROA:-13.01%

PB:4.41

PE(LYR):-3.85

Loading ...

Overview Company News Filings

Industrial Minerals Ltd-Geophysics Confirms Strong Gold Target at Laverton

THOMSON REUTERS

Industrial Minerals Ltd-Results of Meeting

THOMSON REUTERS

Trump: University of Miami donates 1994 Ibogaine IND to accelerate treatment for veterans

Trump's Truth Social latest posts

Caliway Biopharma Submits China Phase 1 IND for CBL-514 Fat-Reduction Drug

MT Newswires Live

Celltrion Submits Dual-Part EMA Application for Subcutaneous Rheumatoid Arthritis Drug

MT Newswires Live

Celltrion Submits Amendment for Phase 3 Trial of Cancer Biosimilar to US FDA

MT Newswires Live

BUZZ-Australia's Industrial Minerals jumps on onshore gold find

Industrial Minerals Ltd-High-Grade Historic Gold Results Confirmed at Laverton

THOMSON REUTERS

Antengene Secures China IND Approval for Autoimmune Disease Drug

MT Newswires Live

Telix Pharmaceuticals Says Prostate Cancer Treatement Candidate Shows Acceptable Tolerability in Phase Three Trial

MT Newswires Live

Nuance Pharma Announces IND Clearance for Actair® Pivotal Clinical Trial in China

Industrial Minerals Ltd-Response to ASX Aware Query

THOMSON REUTERS

Industrial Minerals Ltd-Application for Quotation of Securities - Ind

THOMSON REUTERS

Antengene Appoints Dr. Bing Hou as Chief Scientific Officer to Lead Innovation-Driven R&D Strategy and Advance Next-Generation Pipeline

Industrial Minerals To Acquire Drill Proven Gold Portfolio

BUZZ-Industrial Minerals at 7-month high on Laverton Gold Portfolio acquisition

Kelun-Biotech Receives Investigational New Drug Approval from CDE for SKB118, a PD-1 x VEGF Bispecific Antibody

Industrial Minerals Ltd-Laverton Gold Project Presentation

THOMSON REUTERS

Industrial Minerals Ltd - Acquisition Valued at a$4.67 Mln in Shares With 2.0% Nsr Royalty

THOMSON REUTERS

Industrial Minerals Ltd - Conducting Two-Tranche Placement of up to a$3 Mln at a$0.10 per Share

THOMSON REUTERS

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.etasphere.com/stock/IND.AU/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"IND.AU","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:true,,method:\"POST\",data:#items:@#symbol:\"IND.AU\",,,,,undefined,":{"symbol":"IND.AU","market":"AU","secType":"STK","nameCN":"Industrial Minerals Ltd","latestPrice":0.115,"timestamp":1787530943189,"preClose":0.115,"halted":0,"volume":0,"delay":0,"changeRate":0,"nameEN":"Industrial Minerals Ltd","floatShares":42536073,"shares":100322500,"eps":-0.009145,"marketStatus":"Trading","change":0,"latestTime":"08-24 10:22:23 AEST","open":0.115,"high":0.115,"low":0.115,"amount":3159.3698701949997,"amplitude":0,"askPrice":0.12,"askSize":37617,"bidPrice":0.105,"bidSize":100500,"shortable":3,"etf":0,"ttmEps":-0.009145,"tradingStatus":2,"nextMarketStatus":{"tag":"Closed","tradingStatus":0,"beginTime":1787551200000},"marketStatusCode":2,"adr":0,"exchange":"ASX","adjPreClose":0.115,"openAndCloseTimeList":[[1787529600000,1787551200000]],"volumeRatio":0,"lotSize":1,"tradeCurrency":"AUD","auctionPricing":{"symbol":"IND.AU","preClose":0.115,"auctionPrice":0.12,"auctionVolume":4049,"auctionTime":1787529546111,"referenceTime":1786962603093,"auction":1,"marketStatus":"盘前竞价","timestamp":1787529546111}},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:true,,method:\"POST\",data:#items:@#symbol:\"IND.AU\",,,,,undefined,":{"symbol":"IND.AU","floatShares":42536073,"roa":"-13.01%","roe":"-24.45%","lyrEps":-0.02987,"shares":100322500,"dividePrice":0,"high":0.115,"amplitude":0,"preClose":0.115,"low":0.115,"week52Low":0.092,"pbRate":"4.41","psRate":"13783.86","week52High":0.2,"institutionHeld":0,"latestPrice":0.115,"committee":0.455288,"eps":-0.009145,"divideRate":0,"volume":0,"delay":0,"ttmEps":-0.009145,"open":0.115,"prevYearClose":0.13,"prevWeekClose":0.115,"prevMonthClose":0.096,"prevQuarterClose":0.14,"fiveDayClose":0.12,"twentyDayClose":0.12,"sixtyDayClose":0.15},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/IND.AU\",params:#limit:5,,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"IND.AU\",market:\"AU\",,,undefined,":[],"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"IND.AU\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2661163246","title":"Industrial Minerals Ltd-Geophysics Confirms Strong Gold Target at Laverton","url":"https://stock-news.laohu8.com/highlight/detail?id=2661163246","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2661163246?lang=en_us&edition=fundamental","pubTime":"2026-08-24 06:03","pubTimestamp":1787522599,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260823:nTUEBCXRJD:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7095","IND.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2661592912","title":"Industrial Minerals Ltd-Results of Meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2661592912","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2661592912?lang=en_us&edition=fundamental","pubTime":"2026-08-21 11:05","pubTimestamp":1787281548,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260821:nTUE9Q1DRT:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7095","IND.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660949985","title":"Trump: University of Miami donates 1994 Ibogaine IND to accelerate treatment for veterans","url":"https://stock-news.laohu8.com/highlight/detail?id=2660949985","media":"Trump's Truth Social latest posts","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2660949985?lang=en_us&edition=fundamental","pubTime":"2026-08-19 00:57","pubTimestamp":1787072260,"startTime":"0","endTime":"0","summary":"President Donald Trump announced on August 18 that the University of Miami has donated its original 1994 Ibogaine Investigational New Drug (IND) application to the federal government, a move he said...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"724a78f70d7146f1ab07ec048eae1639","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://trumpstruth.org/statuses/40964","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7095","IND","IND.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2656261587","title":"Caliway Biopharma Submits China Phase 1 IND for CBL-514 Fat-Reduction Drug","url":"https://stock-news.laohu8.com/highlight/detail?id=2656261587","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2656261587?lang=en_us&edition=fundamental","pubTime":"2026-08-04 14:19","pubTimestamp":1785824364,"startTime":"0","endTime":"0","summary":"Caliway Biopharmaceuticals  submitted an investigational new drug  application to China's National Medical Products Administration's Center for Drug Evaluation for a phase one study of abdominal fact reduction drug.The CBL-0102 trial will evaluate the safety, tolerability and pharmacokinetic profile of CBL-514 in about 30 healthy Chinese subjects, following completion of a pre-IND meeting with the regulator.The company said the localized phase 1 study will assess potential racial differences in the drug's efficacy and safety between Chinese and non-Chinese populations, with a China phase 3 application planned after the phase 1 study is completed.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["IND.AU","IND","BK4080","CBL","BK7095","BK4231"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2653088115","title":"Celltrion Submits Dual-Part EMA Application for Subcutaneous Rheumatoid Arthritis Drug","url":"https://stock-news.laohu8.com/highlight/detail?id=2653088115","media":"MT Newswires Live","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2653088115?lang=en_us&edition=fundamental","pubTime":"2026-07-24 17:23","pubTimestamp":1784885030,"startTime":"0","endTime":"0","summary":"Celltrion  has submitted applications for its subcutaneous rheumatoid arthritis drug CT-P13 SC  to both the U.S. FDA  and the European Medicines Agency .The company seeks to demonstrate superiority over placebo at 12 weeks in a 296-patient, 52-week global Phase 3 trial, according to a bourse filing on Friday.The subcutaneous formulation, already approved for ulcerative colitis and Crohn's disease in multiple regions, aims to expand its indications and improve patient convenience through a broader treatment population.The company cautions that historically only about 10% of clinical trial drugs ultimately receive marketing approval, and results may fall short of expectations.While both filings share the same clinical design and commercial rationale, the EMA submission explicitly addresses the EU's revised Clinical Trials Regulation requiring separate Part 1  and Part 2  approvals.Both submissions support commercial differentiation through patient diversity, though investors are urged to","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK7095","IND","EMA","IND.AU","BK4081"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2649118606","title":"Celltrion Submits Amendment for Phase 3 Trial of Cancer Biosimilar to US FDA","url":"https://stock-news.laohu8.com/highlight/detail?id=2649118606","media":"MT Newswires Live","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2649118606?lang=en_us&edition=fundamental","pubTime":"2026-07-07 12:17","pubTimestamp":1783397876,"startTime":"0","endTime":"0","summary":"Celltrion  submitted an investigational new drug  amendment for a global Phase 3 trial of CT-P51, the biosimilar of its cancer drug Keytruda, to the U.S. Food & Drug Administration, according to a Monday filing with the Korea Exchange.The randomized, double-blind, active-controlled clinical trial will enroll 220 previously untreated patients who have metastatic non-squamous non-small cell lung cancer to compare the efficacy and safety of CT-P51 against the reference drug over a two-year treatment period, the filing said.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4585","BK7095","IND.AU","BK4588","LABU","IND"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2645014973","title":"BUZZ-Australia's Industrial Minerals jumps on onshore gold find","url":"https://stock-news.laohu8.com/highlight/detail?id=2645014973","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2645014973?lang=en_us&edition=fundamental","pubTime":"2026-06-22 08:47","pubTimestamp":1782089247,"startTime":"0","endTime":"0","summary":"BUZZ-Australia's Industrial Minerals jumps on onshore gold find** Shares of Industrial Minerals IND.AX rise as much as 12% to A$0.14, hitting their highest level since June 10** Stock marks strongest intraday trading session since May 28** Diversified miner confirms widespread gold mineralisation at onshore Laverton Gold Project** Stock up 7.7% YTD, including current session moves  ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260622:nL4N42U023:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7095","IND.AU","FML.AU","BK7104"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2645601992","title":"Industrial Minerals Ltd-High-Grade Historic Gold Results Confirmed at Laverton","url":"https://stock-news.laohu8.com/highlight/detail?id=2645601992","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2645601992?lang=en_us&edition=fundamental","pubTime":"2026-06-22 06:15","pubTimestamp":1782080138,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260621:nTUE20RCLT:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7095","IND.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2642415735","title":"Antengene Secures China IND Approval for Autoimmune Disease Drug","url":"https://stock-news.laohu8.com/highlight/detail?id=2642415735","media":"MT Newswires Live","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2642415735?lang=en_us&edition=fundamental","pubTime":"2026-06-10 08:31","pubTimestamp":1781051482,"startTime":"0","endTime":"0","summary":"Antengene (HKG:6996) said China's National Medical Products Administration has approved an Investigational New Drug (IND) application for a Phase I study of ATG-201, according to a voluntary filing on","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK7095","IND","BK1574","BK1191","06996","BK1583","IND.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640906993","title":"Telix Pharmaceuticals Says Prostate Cancer Treatement Candidate Shows Acceptable Tolerability in Phase Three Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2640906993","media":"MT Newswires Live","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2640906993?lang=en_us&edition=fundamental","pubTime":"2026-06-02 08:38","pubTimestamp":1780360721,"startTime":"0","endTime":"0","summary":"Telix Pharmaceuticals (ASX:TLX) said its lutetium radio antibody-drug conjugate candidate, TLX591-Tx, demonstrated acceptable tolerability across all standard-of-care combination groups in the ProstAC","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["TLX.AU","IND.AU","BK4139","BK7095","BK7067","TLX","IND"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2637361871","title":"Nuance Pharma Announces IND Clearance for Actair® Pivotal Clinical Trial in China","url":"https://stock-news.laohu8.com/highlight/detail?id=2637361871","media":"prnewswire","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2637361871?lang=en_us&edition=fundamental","pubTime":"2026-05-22 09:50","pubTimestamp":1779414600,"startTime":"0","endTime":"0","summary":"NMPA Approval Marks Key Milestone in Advancing House Dust Mite Allergy Immunotherapy to Chinese Patients. Actair is already commercialized across 21 countries and territories , with further market expansions underway.The IND clearance follows a series of recent milestones reinforcing Nuance Pharma's commitment to the Chinese allergy market.In September 2025, the company entered into an exclusive long-term partnership with Stallergenes Greer for the development and registration of the company'sActair tablet in China, with Nuance Pharma retaining responsibility for subsequent commercialization. In January 2026,Actair received approval from the Pharmaceutical Administration Bureau of Macau. Most recently, in May 2026, Nuance Pharma launched Actair in China's Hainan Boao Pilot Zone through an early access program.Dr. Andreas Amrein, Chairman and Chief Executive Officer of Stallergenes Greer, added: \"This IND clearance is a significant achievement for our development partner, Nuance Pharma,","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.prnewswire.com/apac/news-releases/nuance-pharma-announces-ind-clearance-for-actair-pivotal-clinical-trial-in-china-302779685.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7095","BK4551","BK4561","NUAN","IND","IND.AU","BK4023"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2637380118","title":"Industrial Minerals Ltd-Response to ASX Aware Query","url":"https://stock-news.laohu8.com/highlight/detail?id=2637380118","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2637380118?lang=en_us&edition=fundamental","pubTime":"2026-05-21 13:36","pubTimestamp":1779341798,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260521:nTUE1VLDTC:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7095","IND.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2636969608","title":"Industrial Minerals Ltd-Application for Quotation of Securities - Ind","url":"https://stock-news.laohu8.com/highlight/detail?id=2636969608","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2636969608?lang=en_us&edition=fundamental","pubTime":"2026-05-20 09:17","pubTimestamp":1779239851,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260520:nTUE8NKB5D:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7095","IND.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2636899893","title":"Antengene Appoints Dr. Bing Hou as Chief Scientific Officer to Lead Innovation-Driven R&D Strategy and Advance Next-Generation Pipeline","url":"https://stock-news.laohu8.com/highlight/detail?id=2636899893","media":"prnewswire","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2636899893?lang=en_us&edition=fundamental","pubTime":"2026-05-20 08:00","pubTimestamp":1779235200,"startTime":"0","endTime":"0","summary":"SHANGHAI and HONG KONG, May 20, 2026 /PRNewswire/ -- Antengene Corporation Limited , a leading innovative, commercial-stage global biotech company dedicated to discovering, developing and commercializing first-in-class and/or best-in-class medicines for autoimmune disease, solid tumors and hematological malignancies indications, today announced that Dr. Bing Hou has been appointed Chief Scientific Officer, reporting directly to Dr. Jay Mei, Founder, Chairman, and Chief Executive Officer of Antengene.Dr. Hou's appointment underscores Antengene's commitment to strengthening its innovation-driven R&D model as a global biotech company. In this role, Dr. Hou will lead Antengene's efforts across Drug Discovery, Translational Medicine, and Chemistry, Manufacturing and Controls , with a focus on deepening the Company's research engine and building a pipeline of next-generation therapeutic candidates with transformational potential.\"I am honored and excited to step into the role of Chief Scient","market":"other","thumbnail":"https://mma.prnewswire.com/media/2355066/ANTENGENE_EN_Logo.jpg?w=300","type":0,"news_type":0,"thumbnails":["https://mma.prnewswire.com/media/2355066/ANTENGENE_EN_Logo.jpg?w=300"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.prnewswire.com/apac/news-releases/antengene-appoints-dr-bing-hou-as-chief-scientific-officer-to-lead-innovation-driven-rd-strategy-and-advance-next-generation-pipeline-302776389.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00B7SZL793.SGD","LU2746668461.USD","LU2237443895.HKD","IE00B66KJ199.SGD","IE00B19Z4B17.USD","BK4231","LU0963586101.USD","LU0971096721.USD","LU2237443978.SGD","IE00BFXG1179.USD","LU0267386448.USD","LU1363072403.SGD","LU0170899867.USD","IND","DBB","CRS.AU","LU2746668974.SGD","ADC","IE00BKVL7J92.USD","LU0149725797.USD","IE00BHPRN162.USD","CMC","LU2237443382.USD","LU2237443465.HKD","LU2237443622.USD","IE0031619046.USD","BK4006","IE00BZ1G4Q59.USD","LU0882574139.USD","BK4080","CRS","LU2237443549.SGD","BK4187","ADC.AU","LU2065731478.USD","IND.AU","BK7095","IE00B1BXHZ80.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635272749","title":"Industrial Minerals To Acquire Drill Proven Gold Portfolio","url":"https://stock-news.laohu8.com/highlight/detail?id=2635272749","media":"Reuters","labels":["shareholding","corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635272749?lang=en_us&edition=fundamental","pubTime":"2026-05-13 14:12","pubTimestamp":1778652765,"startTime":"0","endTime":"0","summary":"May 13 (Reuters) - Industrial Minerals Ltd ::*IND TO ACQUIRE DRILL PROVEN GOLD PORTFOLIO*ACQUISITION VALUED AT A$4.67 MILLION IN SHARES WITH 2.0% NSR ROYALTY*CONDUCTING TWO-TRANCHE PLACEMENT OF UP TO ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260513:nRSD2slTQd:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding,corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7095","IND.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635227863","title":"BUZZ-Industrial Minerals at 7-month high on Laverton Gold Portfolio acquisition","url":"https://stock-news.laohu8.com/highlight/detail?id=2635227863","media":"Reuters","labels":["merge"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635227863?lang=en_us&edition=fundamental","pubTime":"2026-05-13 10:41","pubTimestamp":1778640087,"startTime":"0","endTime":"0","summary":"BUZZ-Industrial Minerals at 7-month high on Laverton Gold Portfolio acquisition** Shares of Industrial Minerals IND.AX rise as much as 6.1% to A$0.2, their highest level since September 2, 2025** On track to log its best session since April 27** Mineral explorer to acquire Laverton Gold Portfolio, consisting of 15 exploration licences covering about 205km** Portfolio located within highly prospective Laverton Tectonic Zone, one of Australia's premier orogenic gold districts** Additionally, co is conducting a two-tranche placement of up to A$3 million  to fund the Laverton Gold Project exploration programme, working capital** About 1.4 mln shares traded so far, 10.7x the 30-day avg** Up 34.6% YTD, including the session's moves","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260513:nL6N41Q06A:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"merge","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7104","FML.AU","BK7095","IND.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635221989","title":"Kelun-Biotech Receives Investigational New Drug Approval from CDE for SKB118, a PD-1 x VEGF Bispecific Antibody","url":"https://stock-news.laohu8.com/highlight/detail?id=2635221989","media":"prnewswire","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635221989?lang=en_us&edition=fundamental","pubTime":"2026-05-13 08:00","pubTimestamp":1778630400,"startTime":"0","endTime":"0","summary":"CHENGDU, China, May 12, 2026 /PRNewswire/ --Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.  announced that it has received a clinical trial notice from the Center for Drug Evaluation  of the National Medical Products Administration  approving the Investigational New Drug  application for PD-1 x VEGF bispecific antibody SKB118  for the treatment of advanced solid tumors.In December 2025, Kelun-Biotech and Crescent Biopharma  entered into a strategic collaboration for SKB118/CR-001. Under the collaboration, Crescent granted Kelun-Biotech exclusive rights to research, develop, manufacture and commercialize SKB118/CR-001 in Greater China . In January 2026, Crescent announced the regulatory clearance of the IND application for SKB118/CR-001 by the U.S. Food and Drug Administration  to initiate its global ASCEND Phase I/II clinical trial  for the treatment of locally advanced or metastatic solid tumors. The trial is ongoing and expected to initially enroll up to 290 patients.","market":"nz","thumbnail":"https://mma.prnewswire.com/media/2650617/logo_kelun_Biotech_Logo.jpg?w=300","type":0,"news_type":0,"thumbnails":["https://mma.prnewswire.com/media/2650617/logo_kelun_Biotech_Logo.jpg?w=300"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.prnewswire.com/apac/news-releases/kelun-biotech-receives-investigational-new-drug-approval-from-cde-for-skb118-a-pd-1-x-vegf-bispecific-antibody-302769694.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7050","IND.AU","LU1223082196.USD","LU1223082519.USD","BK4023","BK4017","BK4588","LU1169589451.USD","BK7095","LU1169590202.USD","BK4585","XBI","IND","PD","CDE.AU","CDE","BK4581","LU1223083913.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635221846","title":"Industrial Minerals Ltd-Laverton Gold Project Presentation","url":"https://stock-news.laohu8.com/highlight/detail?id=2635221846","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635221846?lang=en_us&edition=fundamental","pubTime":"2026-05-13 07:55","pubTimestamp":1778630119,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260512:nTUE8FFL1X:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["IND.AU","BK7095"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635322184","title":"Industrial Minerals Ltd - Acquisition Valued at a$4.67 Mln in Shares With 2.0% Nsr Royalty","url":"https://stock-news.laohu8.com/highlight/detail?id=2635322184","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635322184?lang=en_us&edition=fundamental","pubTime":"2026-05-13 07:54","pubTimestamp":1778630096,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260512:nTUE2N49XY:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["IND.AU","BK7095"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635221845","title":"Industrial Minerals Ltd - Conducting Two-Tranche Placement of up to a$3 Mln at a$0.10 per Share","url":"https://stock-news.laohu8.com/highlight/detail?id=2635221845","media":"THOMSON REUTERS","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635221845?lang=en_us&edition=fundamental","pubTime":"2026-05-13 07:54","pubTimestamp":1778630096,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260512:nTUE2N49XY:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7095","IND.AU"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":2,"pageCount":1,"totalSize":37,"code":"91000000","status":"200"}]}}